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Abstract Immunoglobulin A nephropathy is now recog-
nized as the glomerular disease most often associated with
progressive renal failure in patients around the world. In
many cases it is not known when the disease starts to inflict
glomerular injury, but recent studies that have shown
genetically determined abnormalities in glycosylation of
the IgA molecule suggest that this may begin in early life.
This review focuses on recent advances in our understand-
ing of IgA nephropathy, with special emphasis on clinical
aspects of the disease when it presents in children and
adolescents. In addition, the sections dealing with thera-
peutic options for patients with IgA nephropathy concen-
trate on studies that have been carried out on children.
Whenever possible, data from randomized controlled
clinical trials have formed the basis for recommendations.
Unfortunately, this is not always possible, because of the
lack of such trials in patients with IgA nephropathy.
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Introduction
Immunoglobulin A nephropathy (IgAN), a condition
originally called Berger’s disease, is defined by the
presence of IgA deposits in glomerular mesangial areas,
sometimes associated with IgA deposits in other areas of
the glomeruli [1, 2]. These deposits may be accompanied
by other immunoreactants, but the IgA deposits are always
dominant or co-dominant. Early descriptions of the condi-
tion in children indicated that it was relatively mild [3, 4].
However, it is now known that histologic abnormalities and
the clinical course of patients with IgAN may range from
almost normal to very severe—in both children and adults
[5–8]. In the later stages of disease, glomerulosclerosis may
predominate. Although the renal lesions in children with
Henoch–Schönlein purpura (HSP) are also characterized by
mesangial IgA deposition [9], the features of HSP nephritis
are not considered in this review.
Epidemiology
IgAN was first described by Jean Berger in 1968 [1]. Since
then, it has become recognized as the most common form
of glomerulonephritis in both children and adults in many
parts of the world. This is particularly evident in countries
such as Japan and Korea, where annual mass screening of
school children is carried out [10, 11]. In those countries,
IgAN is diagnosed in 30–40% of the patients who have
undergone a kidney biopsy to determine the diagnosis in
children with hematuria with or without proteinuria.
Diagnosis
The diagnosis of IgAN requires a renal biopsy. Although
elevated levels of serum IgA are sometimes observed in
patients with IgAN, this finding is too inconsistent to be of
diagnostic help. Currently, there are no non-invasive
techniques that can establish the diagnosis of IgAN.
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The degree of histopathologic injury varies between
patients [2, 5–8]. In most cases, there is focal or diffuse
mesangial hypercellularity that may vary from mild to
severe. Mesangial hypercellularity is accompanied by an
increase in mesangial matrix. Endocapillary lesions, which
may be proliferative or sclerosing, are also seen in some
patients. Crescentic glomerulonephritis, in which more than
50% of glomeruli contain crescents, is observed in
approximately 5% of cases [2]. In patients with progressive
disease, tubular injury often results in fibroproliferative
changes. Immunofluorescence studies are mandatory for the
diagnosis of IgAN. The presence of IgA in the glomeruli is
usually demonstrated by immunofluorescence of unstained
frozen sections. Complement component 3 (C3) is usually
present and IgG and IgM are seen in approximately 50% of
biopsies [2, 8]. Electron microscopy usually shows electron-
dense deposits only in mesangial areas. However, capillary-
wall deposits may also be seen in approximately 30% of
biopsies. In rare cases there may be a membranoproliferative
pattern.
Clinicopathologic correlations
The presence of glomerulosclerosis, fibrous crescents,
interstitial fibrosis, or tubular atrophy provides the most
reliable histologic indicator of a poor outcome. It is
important to distinguish between chronic irreversible
lesions and potentially reversible lesions that may respond
to therapy.
Etiology
The etiology of IgAN remains unclear [12]. The fact that
hematuria following an episode of upper respiratory
infection is observed in many patients with IgAN has led
to the view that IgAN is a complication of such infections,
but no individual viral or bacterial organism has been
consistently associated with IgAN. It has also been
proposed that IgAN might be caused by hypersensitivity
to food antigens. However, there is no evidence of
hypersensitivity to food antigens in most patients with
IgAN.
Pathogenesis
IgA is produced in two forms, IgA1 and IgA2, and is
secreted from mucosal surfaces, with very little reaching the
systemic circulation [12]. Increased levels of circulating
IgA immune complexes have been documented in some
patients with IgAN. However, attempts to correlate these
complexes with disease activity have not produced consis-
tent findings. It has recently been proposed that some
patients with IgAN have IgA molecules with some
abnormal characteristics that lead to mesangial deposition.
This proposed molecular abnormality involves a defect in
glycosylation of the IgA1 hinge region [12]. Initial reports
of abnormal galactosylation of IgA1 O-glycans involved
studies that demonstrated abnormalities in the molecular
structure of serum IgA, but recent studies have shown the
same O-glycosylation abnormalities in IgA immune depos-
its in the glomeruli of IgAN patients [13]. Abnormally
galactosylated IgA has also been found in the urine of
patients with IgAN. Altered sialylation of IgA1 has also
been described.
Genetics
It has been postulated that both genetic and environmental
factors may be responsible for the variable prevalence of
IgAN around the world, which is most pronounced in
southeast Asia. In recent years many families with biopsy-
proven IgAN have been described. Some patients share
with their asymptomatic blood relatives the abnormality in
glycosylation of the IgA1 molecule discussed above. In
contrast, individuals who married into these families did not
exhibit this defect in glycosylation.
The potential role of an individual’s genetic predisposi-
tion to the development of IgAN in the USA was
established by a large study that was carried out in eastern
Kentucky [14]. It was found that 53 of 96 (55%) IgAN
patients in eastern or central Kentucky had at least one
relative with IgAN. In some parts of Europe up to 10% of
patients with IgAN have a family history of renal disease. If
hematuria is used as the criterion for IgAN, familial disease
may be responsible for 10–15% of all cases in northern
Italy and eastern Kentucky. However, it is likely that most
of a cohort’s family members will not develop clinically
progressive disease.
Clinical presentation
The initial clinical features observed in children with IgAN
are quite variable, with some being identified as a result of
urinary screening as opposed to others who develop overt
clinical symptoms or signs. A good example of the first
situation exists in Japan and Korea, where many children
are diagnosed with IgAN after hematuria with or without
proteinuria has been discovered during the annual school
screening programs that exists in these two countries [10,
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trials, wherein 63 (59%) of 106 patients enrolled in the
trials were diagnosed after they were found to have urinary
abnormalities via the Japanese school screening program
[15, 16]. A similar situation was recently reported by Park
et al., who described biopsy findings in 113 children who
were identified by the Korean school screening program
[11]. Thirty-four of 51 (66%) biopsied children with
hematuria/proteinuria were diagnosed with IgAN.
Other children with IgAN present with more overt
clinical findings. The original descriptions of the disease
emphasized synpharyngitic presentations, i.e. an episode of
gross hematuria coincident with an upper respiratory
infection [1, 2]. This is the most frequent mode of
presentation in children and young adults in the Western
hemisphere [2, 4, 8]. A smaller number of patients show
clinical signs of the nephritic or nephrotic syndrome.
Natural history and prognosis
The natural history of IgAN is quite variable [2–8]. Some
children have recurrent episodes of gross hematuria,
whereas others remain asymptomatic and may show no
overt clinical features. When they occur, the episodes of
hematuria are often associated with upper respiratory
infections but are usually short-lived, sometimes resolving
within a day or two. Up to 20% of pediatric patients with
IgAN have progressive disease, leading eventually to end-
stage renal disease [5, 6]. In most such cases the rate of
progression of disease is usually very slow. This makes it
very difficult for the nephrologist to evaluate the level of
success of any therapeutic intervention that is employed.
Clinical features which mark a poor prognosis include
moderate to severe degrees of proteinuria, renal insuffi-
ciency at the time of renal biopsy and hypertension [3–6].
Renal biopsy features that portend a poor prognosis include
glomerulosclerosis, fibrous crescents, tubular atrophy and
interstitial fibrosis [3–8]. In most patients the level of
proteinuria appears to correlate closely with the severity
of renal parenchymal disease and risk of progression.
Although none of these prognostic indicators has sufficient
specificity to identify the outcome of an individual patient,
it is clear that children with hypertension and/or severe
proteinuria are most likely to have progressive disease and
should be regarded as prime candidates for therapeutic
intervention [2, 5, 6].
Approach to therapy in children with IgAN
At some point in the future it is likely that the focus of
treatment for patients with IgAN will be to reverse the
pathogenetic processes that result in the disease. Hence, the
therapy might correct defects in IgA1 glycosylation, and/or
prevent mesangial deposition of IgA immune complexes.
However, such treatment options are not currently avail-
able. At the present time, therapeutic strategies are directed
at downstream immune and inflammatory processes in the
glomerulus and the tubulo-interstitium that are associated
with proteinuria and progressive renal damage.
Current options for therapy of individual patients
One of the guiding principles that should be foremost in the
minds of pediatric nephrologists when approaching a child
or adolescent with IgAN is that aggressive therapeutic
measures should not be employed for patients who are not
likely to develop progressive disease. This is also true for
patients for whom there is no realistic chance of recovery,
i.e. patients with diffuse glomerulosclerosis who have
reached chronic kidney disease stages 4 or 5 [17]. These
patients are considered to have reached “the point of no
return”. The following sections consider how treatment
should be tailored to patients with varying degrees of
disease severity. Unfortunately, most of the recommenda-
tions are based on less than stellar evidence [18].
(a) Patients with microscopic hematuria and/or low-grade
proteinuria: it is not known whether therapy is
necessary for such patients, although they should
undergo regular follow-up examinations. Some reports
indicate that vitamin E supplements may be effica-
cious in this group of patients [19]. A threshold for
more aggressive therapy that has found general
acceptance is proteinuria greater than 1 g/1.73 m
2
body surface area per 24 h. This level of proteinuria is
equivalent to a urine protein:creatinine ratio of 0.6 in
male patients and 0.8 in female patients. Recent reports
favor the initiation of treatment with angiotensin-
converting enzyme inhibitors (ACEis) or angiotensin
receptor blockers (ARBs) for patients with these grades
of proteinuria. This is discussed below.
(b) Patients with recurrent gross hematuria: episodes of
gross hematuria appear to be of little long-term
consequence for patients with IgAN. Most studies of
adults even report that a history of gross hematuria is
associated with a better prognosis. Studies of this
issue in children have produced mixed results.
Tonsillectomy has been recommended by some
investigators for patients with IgAN complicated by
gross hematuria, especially those with a history of
frequent episodes of tonsillitis. Reports of this
approach in children have been predominantly retro-
spective studies and have not included adequate
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evidence that tonsillectomy induces long-term renal
protection. However, most of the patients reported in
these studies have also received concomitant medi-
cations such as corticosteroids. This makes the data
difficult to interpret [18]. In general, it is recommen-
ded that a conservative approach be maintained for
children with recurrent gross hematuria unless they
develop additional risk factors.
(c) Children with combined clinical and pathologic risk
factors: as noted above, more aggressive treatment
measures should be reserved for children and adoles-
cents with features consistent with a high risk of
progressive renal dysfunction, such as hypertension,
severe proteinuria and/or reduced glomerular filtration
rate (GFR) at the time of renal biopsy, plus histologic
lesions such as glomerulosclerosis and/or proliferation.
Unfortunately, large controlled studies with prolonged
follow-up that compare the various treatment strategies
in such patients are lacking [18]. Even well-designed
studies of progressive IgAN that have been recently
published have involved relatively few patients and
short periods of follow-up [20]. In addition, many trials
of children with IgAN have depended mainly on
clinical entry criteria—typically the presence of hyper-
tension and proteinuria—in patients who may have a
wide array of pathologic findings [18, 20, 21].
A variety of approaches has been employed in attempts
to prevent, or at least delay, progressive renal damage in
children and adults with severe manifestations of IgAN.
Many authors propose that the initial goals in IgAN
patients with hypertension and/or proteinuria should be to
establish a normal blood pressure, based on age, gender and
height [22], and to reduce proteinuria via blockade of the
renin–angiotensin system (RAS) without resorting to
immunosuppressive drugs. A recent multicenter collabora-
tive study in Europe has shown that this approach may
provide significant reduction in proteinuria and preserva-
tion of GFR [20].
Other investigators believe that the initial treatment of
children with high-risk IgAN should incorporate immuno-
suppressive medications and that therapy oriented towards
the renin–angiotensin system is of less importance. The
large multicenter studies in Japan have concentrated on
immunosuppressive medications and have even prohibited
the use of ACEis in their study patients. A third approach to
therapy is to employ a stepwide strategy wherein ACEi is
tried first and immunosuppressive medications are reserved
for patients who show a poor response to ACEis [21]. The
next few sections describe the various approaches that have
used corticosteroids with or without other immunosuppres-
sive medications in children with IgAN.
Corticosteroids as monotherapy
A trial of high doses of corticosteroids should be
considered for children presenting with clinical features of
nephrotic syndrome and renal biopsy findings that are
otherwise consistent with minimal change disease (MCD)
[23–25]. This scenario is relatively rare, but the response of
the patients is usually comparable to that seen in children
with MCD without IgA deposits. The relationship between
the two conditions is unclear.
Results obtained with corticosteroids in children with
more significant renal lesions are less certain.
The short-term effect of prednisone on the severity of
hematuria in 20 children with milder degrees of proteinuria
was examined by Welch et al. [26]. The patients were
randomly chosen to be given either placebo or prednisone
(2 mg/kg per day) for 2 weeks, followed by the same doses
on alternate days for 10 weeks. No difference in the
severity of hematuria was reported in the two groups. It
should be noted, however, that most of the patients in that
study showed relatively mild histologic changes.
In a retrospective study of patients with more severe
renal histologic changes, Waldo et al. compared 13 children
with IgAN who received prednisone on alternate days for
2 years with 15 children who received no therapy [27].
Whereas none of the 13 treated patients progressed to end-
stage renal disease (ESRD), this did develop in five of 15
untreated patients. At last follow-up, 12 of the treated
patients had normal findings in their urinalyses.
Corticosteroids plus azathioprine
The efficacy of combination therapy using prednisone and
azathioprine was evaluated by Andreoli and Bergstein [28].
They employed a tapering dose of prednisone in addition to
azathioprine (2–3 mg/kg per day) for 1 year. Proteinuria fell
by 61% from baseline, and the renal biopsy activity score
improved. However, the chronicity score was unchanged.
There was no control group in this study.
In a subsequent randomized controlled trial (RCT), the
Japanese Pediatric IgA Nephropathy Treatment Group
evaluated the efficacy of a 2-year course of prednisone,
azathioprine, heparin, warfarin, and dipyridamole [29]. The
control group received heparin, warfarin and dipyridamole.
The group receiving prednisone and azathioprine had a
significant reduction of proteinuria (1.35→0.22 g per day),
whereas the control did not (0.98→0.88 g per day). Follow-
up biopsies showed that progression of glomerular sclerosis
had occurred only in the control group.
The same Japanese group then conducted a second
RCT, which evaluated the efficacy of prednisone, azathi-
oprine, warfarin and dipyridamole versus a control group
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uria fell to less than 10 mg/m
2 per day in 92% of the group
receiving combination therapy versus 74% of the group
receiving prednisone (P difference=0.007). As in their first
study, they found that the percentage of glomeruli showing
sclerotic changes was unchanged from baseline in the
group receiving combination therapy but that it had
increased significantly in those receiving prednisone alone.
Corticosteroids plus cyclophosphamide
Murakami et al. evaluated the efficacy of a 6-month course
of low doses of prednisone combined with cyclophospha-
mide and dipyridamole in 17 pediatric patients who had
proteinuria >1 g/m
2 per day [30]. The authors noted
significant improvement in proteinuria, but post-therapy
biopsies showed persistent signs of chronic disease.
Additional follow-up in these patients over a period of
5–6 years revealed rebound deterioration of proteinuria.
Mycophenolate mofetil and mizoribine in children
with IgAN
The use of mycophenolate mofetil (MMF) has shown
mixed results in studies of adults with IgAN, but it has not
been studied adequately enough in children for a treatment
recommendation to be made.
Mizoribine, an agent that blocks purine synthesis in a
manner similar to that of MMF, has been reported to be
effective in reducing proteinuria in Japanese children with
IgAN [31, 32]. A recent report by Yoshikawa et al.
indicated that when mizoribine was substituted for azathi-
oprine as part of the combination therapy approach
described above, proteinuria fell from 1.19 g/m
2 per day
to 0.05 g/m
2 per day [16]. In addition, 18 of 23 children
gained complete remission of their proteinuria. The
Japanese Study Group has subsequently embarked on an
RCT to determine if they can confirm the results obtained
in this pilot study.
Omega 3 fatty acids
Based upon the limited evidence available, it is difficult to
recommend the use of omega 3 fatty acids for treatment
of IgAN in pediatric patients, although data from the
North American IgA Nephropathy Trials, which included
both children and adults, indicate that such therapy may
be efficacious in reducing proteinuria in such patients
[33].
Children with crescentic (rapidly progressive) IgAN
The prognosis for children with crescentic IgAN is very poor
intheabsenceofeffectivetherapy[34]. Although there are no
controlled trials of treatment regimens for children with
crescentic IgAN, Niaudet et al. described a good response to
intravenous treatment with methylprednisolone for 2 weeks
at a dose of 1 g/1.73 m
2 q.o.d., followed by 1 month of
prednisone daily (1 mg/kg) and then prednisone on alternate
days for 23 months [35]. The authors also described good
long-term outcomes in most of these patients.
Conclusions
It is apparent from this consideration of IgAN in children
that we still have much to learn about this condition. Until
more specific interventions are discovered, it is recommen-
ded that non-immunosuppressive regimens be tried first in
patients with signs of slowly progressive disease, with
subsequent use of immunosuppressive medications in
patients who do not show a good response.
Questions
(Answers appear following the reference list)
1. Children with IgA nephropathy may present with:
a. gross hematuria
b. microscopic hematuria
c. nephrotic syndrome
d. acute renal failure
e. all of the above
2. Characteristic renal biopsy findings in patients with
IgA nephropathy include:
a. IgG deposits in glomerular capillary walls
b. subepithelial deposits on electron microscopy
c. mesangial hypercellularity plus increase in mesangial
matrix
d. none of the above
e. all of the above
3. Which of the following statements is true?
a. IgA nephropathy can be diagnosed on the basis of
characteristic light and electron microscopy findings
b. IgA nephropathy is a rare diagnosis in Korean
children with hematuria and proteinuria
c. patients with progressive renal disease associated
with IgA nephropathy usually develop end-stage
disease soon after the diagnosis has been made
d. none of the above
e. all of the above
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IgA nephropathy. Which of the following is true?
a. episodes of gross hematuria indicate a rapidly
progressive course
b. in most patients episodes of gross hematuria persist
for 1–2 weeks
c. gastroenteritis often precedes an episode of gross
hematuria
d. none of the above
e. all of the above
5. Which of the following statements is true?
a. treatment of children with corticosteroids has been
found to be ineffective in all studies involving
children diagnosed with IgA nephropathy
b. abnormal glycosylation of the IgA molecule may
be the underlying problem in some patients with
IgA nephropathy
c. omega 3 fatty acids are well established as an
effective treatment for children with IgA nephropathy
d. none of the above
e. all of the above
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